BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
July 20, 2005
View Archived Issues
$525M Gets Emtriva Interest From Emory For Gilead, Royalty Pharma
Gilead Sciences Inc. and Royalty Pharma bought out Emory University's royalty interest in emtricitabine - or Emtriva - for $525 million. (BioWorld Today)
Read More
After Long Wait, Crawford Confirmed As Head Of FDA
Read More
Arakis Providing Exit Via £106.5M Sosei Acquisition
Read More
Ilypsa's Series B Adds $36M For Renal Disease Products
Read More
Correction
Read More
Other News To Note
Read More
Appointments And Advancements
Read More